Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OLF005
MIFTS: 47

Olfactory Neuroblastoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases, Smell/Taste diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Olfactory Neuroblastoma

About this section

MalaCards integrated aliases for Olfactory Neuroblastoma:

Name: Olfactory Neuroblastoma 12 53 59 15 73
Esthesioneuroblastoma 12 76 53 59 55
Paranasal Sinus Olfactory Neuroblastoma 12
Esthesioneuroblastoma, Olfactory 44
Olfactory Esthesioneuroblastoma 12
Esthesioneuroepithelioma 12
Asthesioneuroblastoma 12

Characteristics:

Orphanet epidemiological data:

59
esthesioneuroblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Smell/Taste diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:369
MeSH 44 D018304
NCIt 50 C3789 C6016
Orphanet 59 ORPHA1957
UMLS via Orphanet 74 C0206717
ICD10 via Orphanet 34 C30.0
UMLS 73 C0206717
Sources

Summaries for Olfactory Neuroblastoma

About this section
NIH Rare Diseases : 53 Olfactory neuroblastoma is a rare cancer of the upper part of the nasal cavity called the cribiform plate, which is a bone deep in the skull between the eyes, and above the ethmoid sinuses. It accounts for about 5% of all cancers of the nasal cavity and paranasal sinuses. It develops in nerve tissue associated with the sense of smell (olfactory nerve). It can occur at any age, but typically is found in adulthood. Symptoms may be nonspecific and include a blockage of the nasal passageways due to the tumor, facial pain, runny nose, and nosebleeds. Treatment usually includes surgery to remove the tumor, radiation therapy, and sometimes chemotherapy.

MalaCards based summary : Olfactory Neuroblastoma, also known as esthesioneuroblastoma, is related to sinonasal undifferentiated carcinoma and neuroblastoma. An important gene associated with Olfactory Neuroblastoma is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and Transcriptional misregulation in cancer. The drugs Fentanyl and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and lung, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Esthesioneuroblastoma, also called \"olfactory neuroblastoma\", is a rare cancer of the nasal cavity.... more...

Sources

Related Diseases for Olfactory Neuroblastoma

About this section

Diseases related to Olfactory Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 sinonasal undifferentiated carcinoma 31.1 ENO2 SYP
2 neuroblastoma 31.0 ENO2 NGFR NTRK1 SYP
3 ganglioneuroma 29.5 CHGA ENO2 NTRK1 SYP
4 neuroendocrine tumor 29.4 CHGA ENO2 SSTR2 SYP
5 ewing sarcoma 27.1 CHGA ENO2 EWSR1 PTPRC S100B SYP
6 nasal cavity olfactory neuroblastoma 12.2
7 intracranial primitive neuroectodermal tumor 10.8 CHGA ENO2
8 goblet cell carcinoid 10.7 CHGA ENO2
9 malignant sertoli cell tumor 10.7 ENO2 SYP
10 acute thyroiditis 10.7 CHGA ENO2
11 sensory organ benign neoplasm 10.7 ENO2 SYP
12 pancreatic somatostatinoma 10.7 ENO2 SYP
13 cutaneous ganglioneuroma 10.7 ENO2 SYP
14 extrahepatic bile duct adenocarcinoma 10.7 ENO2 SYP
15 papillary tumor of the pineal region 10.7 ENO2 SYP
16 middle ear adenoma 10.7 ENO2 SYP
17 ovarian carcinosarcoma 10.7 ENO2 SYP
18 central nervous system primitive neuroectodermal neoplasm 10.7 ENO2 SYP
19 cerebellum cancer 10.7 ENO2 SYP
20 subependymal glioma 10.7 ENO2 SYP
21 cerebral neuroblastoma 10.7 ENO2 SYP
22 somatostatinoma 10.7 CHGA ENO2
23 benign ependymoma 10.7 ENO2 SYP
24 malignant teratoma 10.7 ENO2 SYP
25 astroblastoma 10.7 ENO2 SYP
26 duodenal gastrinoma 10.7 CHGA ENO2
27 intracranial cysts 10.7 ENO2 S100B
28 cerebral ventricle cancer 10.7 ENO2 SYP
29 bednar tumor 10.7 ENO2 S100B
30 cerebrum cancer 10.7 ENO2 SYP
31 esophageal neuroendocrine tumor 10.7 CHGA SYP
32 pineal gland cancer 10.7 ENO2 SYP
33 ovarian large-cell neuroendocrine carcinoma 10.6 CHGA SYP
34 supratentorial cancer 10.6 ENO2 SYP
35 mucinous ovarian cystadenoma 10.6 ENO2 SYP
36 adenoma of the pancreas 10.6 CHGA SYP
37 acinar cell cystadenocarcinoma 10.6 CHGA SYP
38 angiomyoma 10.6 ENO2 SYP
39 peritoneal serous adenocarcinoma 10.6 CHGA SYP
40 cellular ependymoma 10.6 CHGA SYP
41 bone benign neoplasm 10.6 ENO2 SYP
42 middle cerebral artery infarction 10.6 ENO2 S100B
43 ossifying fibromyxoid tumor 10.6 ENO2 S100B
44 gastrointestinal neuroendocrine tumor 10.6 CHGA SYP
45 meningeal melanomatosis 10.6 ENO2 SYP
46 cervical clear cell adenocarcinoma 10.6 ENO2 SYP
47 spinal meningioma 10.6 CHGA ENO2
48 spinal canal and spinal cord meningioma 10.6 CHGA ENO2
49 connective tissue benign neoplasm 10.6 ENO2 SYP
50 glomus tumor 10.6 ENO2 SYP

Graphical network of the top 20 diseases related to Olfactory Neuroblastoma:



Diseases related to Olfactory Neuroblastoma
Sources

Symptoms & Phenotypes for Olfactory Neuroblastoma

About this section

GenomeRNAi Phenotypes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.62 SSTR2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.62 NTRK1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.62 SSTR2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.62 NTRK1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.62 SSTR2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.62 EWSR1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.62 EWSR1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.62 SSTR2 CHGA EWSR1 NTRK1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.62 SSTR2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.62 NTRK1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 9.62 CHGA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.62 CHGA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.62 SSTR2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.62 EWSR1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.62 EWSR1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.62 EWSR1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.62 SSTR2
Sources

Drugs & Therapeutics for Olfactory Neuroblastoma

About this section

Drugs for Olfactory Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
3
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
4
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
5
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
6
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
7
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
8
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
9 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
10 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Infective Agents Phase 2, Phase 3,Phase 1
12 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
13 Adjuvants, Anesthesia Phase 3
14 Analgesics Phase 3
15 Analgesics, Opioid Phase 3
16 Anesthetics Phase 3
17 Anesthetics, General Phase 3
18 Anesthetics, Intravenous Phase 3
19 Central Nervous System Depressants Phase 3
20 Narcotics Phase 3
21 Peripheral Nervous System Agents Phase 3,Not Applicable
22 Antifungal Agents Phase 2, Phase 3,Phase 1
23 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
24 Hormone Antagonists Phase 2, Phase 3,Phase 1
25 Hormones Phase 2, Phase 3,Phase 1
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
27 Steroid Synthesis Inhibitors Phase 2, Phase 3
28 Autonomic Agents Phase 3,Not Applicable
29 Cholinergic Agents Phase 3,Not Applicable
30 Neurotransmitter Agents Phase 3,Not Applicable
31 Antineoplastic Agents, Hormonal Phase 3
32 Appetite Stimulants Phase 3
33 Central Nervous System Stimulants Phase 3,Not Applicable
34 Contraceptive Agents Phase 3
35 Contraceptives, Oral Phase 3
36
Megestrol Phase 3 3562-63-8 19090 3080587
37 Antidepressive Agents Phase 3
38 Antidepressive Agents, Tricyclic Phase 3
39 Histamine Antagonists Phase 3
40
Histamine Phosphate Phase 3 51-74-1 65513
41 Psychotropic Drugs Phase 3
42 Antimitotic Agents Phase 3,Phase 2,Phase 1
43 Cola Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable
44
Indinavir Approved Phase 2 150378-17-9 5362440
45
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
46
Cyclophosphamide Approved, Investigational Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
47
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
48
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
49
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
50
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
3 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
4 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
5 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
6 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
7 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
8 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
9 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
10 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
11 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
12 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
13 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
14 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
15 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
16 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
17 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer Completed NCT00007982 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa
18 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
19 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
20 Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients Recruiting NCT02099188 Phase 2 Cisplatin;Docetaxel;5-fluorouracil;Etoposide;Adriamycin;Ifosfamide;Leucovorin
21 Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients Recruiting NCT02099175 Phase 2 Cisplatin;Docetaxel;5-fluorouracil;Etoposide;Adriamycin;Ifosfamide;Leucovorin
22 A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages Recruiting NCT03274414 Phase 2 Cisplatin
23 Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Active, not recruiting NCT01586767 Phase 2
24 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
25 Functional MRI in Finding Hypoxia in Patients Undergoing Chemotherapy and Radiation Therapy for Stage III or Stage IV Head and Neck Cancer Unknown status NCT00896350 Phase 1 chemotherapy
26 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1 everolimus
27 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
28 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
29 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
30 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
31 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
32 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
33 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
34 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
35 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
36 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
37 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
38 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
39 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
40 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
41 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
42 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
43 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
44 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1 HPPH;photodynamic therapy
45 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
46 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1 silicon phthalocyanine 4
47 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
48 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074
49 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733 Not Applicable cyclophosphamide
50 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib

Search NIH Clinical Center for Olfactory Neuroblastoma

Cochrane evidence based reviews: esthesioneuroblastoma, olfactory

Sources

Genetic Tests for Olfactory Neuroblastoma

About this section
Sources

Anatomical Context for Olfactory Neuroblastoma

About this section

MalaCards organs/tissues related to Olfactory Neuroblastoma:

41
Eye, Bone, Lung, Brain, Liver, Skin, Kidney
Sources

Publications for Olfactory Neuroblastoma

About this section

Articles related to Olfactory Neuroblastoma:

(show top 50) (show all 301)
# Title Authors Year
1
DNA methylation-based reclassification of olfactory neuroblastoma. ( 29730775 )
2018
2
Surgical Treatment of Olfactory Neuroblastoma: Major Complication Rates, Progression Free and Overall Survival. ( 29868319 )
2018
3
Olfactory Neuroblastoma. ( 29411144 )
2018
4
Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma. ( 29427030 )
2018
5
Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis. ( 29881306 )
2018
6
Ectopic Cushing's syndrome secondary to olfactory neuroblastoma. ( 29340776 )
2018
7
Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review. ( 29901583 )
2018
8
An unusual manifestation of olfactory neuroblastoma. ( 29535093 )
2018
9
Clinical features and the molecular biomarkers of olfactory neuroblastoma. ( 29921494 )
2018
10
Olfactory Neuroblastoma: A Rare Cause of External Ophthalmoplegia, Proptosis and Compressive Optic Neuropathy. ( 29755824 )
2018
11
Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications. ( 28775129 )
2017
12
Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: Series report and literature review. ( 29061289 )
2017
13
The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival. ( 29103747 )
2017
14
Olfactory Neuroblastoma with Divergent Differentiation: An Unusual Histologic Finding in a Rare Tumor. ( 28168398 )
2017
15
Proton beam therapy for olfactory neuroblastoma. ( 28062086 )
2017
16
Long-term control of olfactory neuroblastoma in a dog treated with surgery and radiation therapy. ( 28653386 )
2017
17
Volumetric analysis of olfactory neuroblastoma skull base laterality and implications on neck disease. ( 28833165 )
2017
18
Assessment of frozen section margin analysis during olfactory neuroblastoma surgery. ( 28349538 )
2017
19
&amp;quot;Syndrome of Inappropriate Antidiuretic Hormone Secretion&amp;quot; as a Diagnostic and a Prognostic Indicator in Olfactory Neuroblastoma. ( 28670560 )
2017
20
Remote orbital recurrence of olfactory neuroblastoma (esthesioneuroblastoma). ( 28362545 )
2017
21
A rare case report of mixed olfactory neuroblastoma: Carcinoma with review of literature. ( 28607817 )
2017
22
Neuroendocrine neoplasms of the head and neck and olfactory neuroblastoma. Diagnosis and classification. ( 28635990 )
2017
23
Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. ( 29226334 )
2017
24
How Behavioral Changes Can Indicate Serious Cerebral Pathology: A Case Report of Concomitant Olfactory Neuroblastoma and Distemper Virus Encephalitis in a Swiss Shepherd Dog. ( 29056700 )
2017
25
OTX1 and OTX2 as possible molecular markers of sinonasal carcinomas and olfactory neuroblastomas. ( 28348423 )
2017
26
Survival outcomes for stage-matched endoscopic and open resection of olfactory neuroblastoma. ( 28945299 )
2017
27
In this issue - July 2017: RHDV vaccine protects against both strains of virus a88A^a88 Olfactory neuroblastoma in a Malamute a88A^a88 Coincidental conditions affecting dysphagia in a Miniature Poodle a88A^a88 Support for storing high-quality bovine colostrum a88A^a88 Sarcoptic mange in koalas a88A^a88 Renal oxalosis in rare Gilbert's potoroos a88A^a88 Novel trypanosomes in a little red flying fox. ( 28653384 )
2017
28
Olfactory neuroblastoma: a single-center experience. ( 28540633 )
2017
29
Outcomes for olfactory neuroblastoma treated with induction chemotherapy. ( 28561956 )
2017
30
Recurrent olfactory neuroblastoma in remote leptomeninges, mimicking intracranial meningioma. ( 27609444 )
2016
31
Neuroendocrine Neoplasms of the Sinonasal Tract: Neuroendocrine Carcinomas and Olfactory Neuroblastoma. ( 26830400 )
2016
32
Olfactory neuroblastoma: A frontal lobe disorder and a runny nose. ( 27022175 )
2016
33
Expression pattern of ISL-1, TTF-1 and PAX5 in olfactory neuroblastoma. ( 27543867 )
2016
34
An isolated orbital mass with proptosis and diplopia: an uncommon metastasis from intracranial olfactory neuroblastoma in a chinese patient. ( 27601919 )
2016
35
Olfactory neuroblastoma: A clinicopathological experience of a rare entity from Pakistan. ( 27375694 )
2016
36
Olfactory neuroblastoma: 14-year experience at an Australian tertiary centre and the role for longer-term surveillance. ( 27917732 )
2016
37
Long-Term Prognostic Analysis after Endoscopic Endonasal Surgery for Olfactory Neuroblastoma: A Retrospective Study of 13 Cases. ( 27806104 )
2016
38
Olfactory Neuroblastoma: Fate of the Neck-A Long-term Multicenter Retrospective Study. ( 26671900 )
2016
39
Endoscopic Endonasal Management of Olfactory Neuroblastoma: A retrospective analysis of 10 patients with quality of life measures. ( 26899467 )
2016
40
Ectopic primary olfactory neuroblastoma of the maxillary sinus. ( 27180059 )
2016
41
Syndrome of inappropriate antidiuretic hormone secretion in a case of olfactory neuroblastoma without anti-diuretic hormone immunoreactivity: A case report and review of the literature. ( 28010942 )
2016
42
Role of (18) F-FDG PET/CT differentiating olfactory neuroblastoma from sinonasal undifferentiated carcinoma. ( 27481043 )
2016
43
Bilateral Synchronous Ectopic Ethmoid Sinus Olfactory Neuroblastoma: A Case Report. ( 27097989 )
2016
44
Genetic and molecular alterations in olfactory neuroblastoma - implications for pathogenesis, prognosis and treatment. ( 27256979 )
2016
45
Olfactory neuroblastoma followed by emergency surgery for symptomatic intradural spinal metastasis: A case report. ( 27625887 )
2016
46
Imaging Characteristics of Olfactory Neuroblastoma (Esthesioneuroblastoma). ( 26949582 )
2016
47
Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report. ( 27149458 )
2016
48
Aberrant Pattern of Cytokeratin Expression in Olfactory Neuroblastoma: A Potential Diagnostic Pitfall. ( 27392748 )
2016
49
Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography. ( 25888953 )
2015
50
Comparison of outcomes for open versus endoscopic approaches for olfactory neuroblastoma: A systematic review and individual participant data meta-analysis. ( 26514662 )
2015
Sources

Variations for Olfactory Neuroblastoma

About this section

Copy number variations for Olfactory Neuroblastoma from CNVD:

7 (show all 31)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 31526 1 28000000 30200000 Gain Olfactory neuroblastoma
2 34250 1 5400000 7200000 Gain Olfactory neuroblastoma
3 41470 10 18700000 22600000 Gain Olfactory neuroblastoma
4 63735 12 120700000 125900000 Gain Olfactory neuroblastoma
5 74688 13 110300000 115169878 Gain CUL4A Olfactory neuroblastoma
6 74689 13 110300000 115169878 Gain TFDP1 Olfactory neuroblastoma
7 75167 13 17900000 115169878 Gain Olfactory neuroblastoma
8 77744 13 47300000 55300000 Gain Olfactory neuroblastoma
9 79881 13 79000000 87700000 Gain Olfactory neuroblastoma
10 91527 15 31200000 33600000 Gain Olfactory neuroblastoma
11 101890 16 47000000 52600000 Gain Olfactory neuroblastoma
12 150427 20 1 27500000 Gain Olfactory neuroblastoma
13 151980 20 27500000 63025520 Gain Olfactory neuroblastoma
14 152120 20 29400000 37600000 Gain Olfactory neuroblastoma
15 154980 20 5100000 12100000 Gain Olfactory neuroblastoma
16 155529 20 56500000 63025520 Gain BRK Olfactory neuroblastoma
17 159453 21 42600000 48129895 Gain Olfactory neuroblastoma
18 163221 22 25900000 29600000 Gain Olfactory neuroblastoma
19 179990 4 1 6000000 Gain Olfactory neuroblastoma
20 181394 4 120800000 191154276 Gain Olfactory neuroblastoma
21 184608 4 17800000 48200000 Gain Olfactory neuroblastoma
22 187607 4 52700000 59500000 Gain Olfactory neuroblastoma
23 190046 4 82400000 93700000 Gain Olfactory neuroblastoma
24 196156 5 159900000 168500000 Gain Olfactory neuroblastoma
25 196538 5 168500000 180915260 Gain Olfactory neuroblastoma
26 213457 6 46200000 51800000 Gain Olfactory neuroblastoma
27 227898 7 72200000 77500000 Gain FZD9 Olfactory neuroblastoma
28 227899 7 72200000 77500000 Gain LIMK1 Olfactory neuroblastoma
29 228591 7 77500000 86400000 Gain Olfactory neuroblastoma
30 251884 9 33200000 36300000 Gain Olfactory neuroblastoma
31 257109 X 1 155270560 Gain Olfactory neuroblastoma
Sources

Expression for Olfactory Neuroblastoma

About this section
Search GEO for disease gene expression data for Olfactory Neuroblastoma.
Sources

Pathways for Olfactory Neuroblastoma

About this section

Pathways related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.56 ENO2 NGFR NTRK1 S100B SYP
2
Transcriptional misregulation in cancer 37
11.4 EWSR1 NGFR NTRK1
Sources

GO Terms for Olfactory Neuroblastoma

About this section

Biological processes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to amyloid-beta GO:1904646 9.16 NGFR NTRK1
2 regulation of neuronal synaptic plasticity GO:0048168 8.96 S100B SYP
3 neurotrophin TRK receptor signaling pathway GO:0048011 8.62 NGFR NTRK1

Molecular functions related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nerve growth factor binding GO:0048406 8.96 NGFR NTRK1
2 neurotrophin binding GO:0043121 8.62 NGFR NTRK1
Sources

Sources for Olfactory Neuroblastoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....